Jump to content

Encainide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 16:13, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Encainide
File:EncainideRedrawn.svg
Clinical data
Trade namesEnkaid
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa605040
ATC code
Legal status
Legal status
  • Withdrawn
Identifiers
  • 4-methoxy-N-[2-(1-methyl-2-piperidin-1-ylethyl)phenyl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28N2O2
Molar mass352.47 g/mol g·mol−1
3D model (JSmol)
  • CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
  • InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) checkY
  • Key:PJWPNDMDCLXCOM-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Encainide (trade name Enkaid) is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects.[1]

Synthesis

Encainide synthesis:[2][3][4]

See also

References

  1. ^ Echt, D. S.; Liebson, P. R.; Mitchell, L. B.; Peters, R. W.; Obias-Manno, D.; Barker, A. H.; Arensberg, D.; Baker, A.; Friedman, L.; Greene, H. L.; Huther, M. L.; Richardson, D. W. (1991). "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo". New England Journal of Medicine. 324 (12): 781–788. doi:10.1056/NEJM199103213241201. PMID 1900101.
  2. ^ S.J. Dykstra, J.L. Minelli, DE 2210154  (1972).
  3. ^ S.J. Dykstra, J.L. Minelli, U.S. patent 3,931,195 (1976).
  4. ^ Dykstra, Stanley J. (1973). "Lysergic acid and quinidine analogs. 2-(o-Acylaminophenethyl)piperidines". Journal of Medicinal Chemistry. 16 (9): 1015–1020. doi:10.1021/jm00267a012. PMID 4745503.